Or Sell: Bsx Stock Buy

Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

As of late April 2026, Boston Scientific (BSX) presents a complex "show-me" story for investors. While Wall Street remains broadly bullish, recent guidance cuts and competitive pressures have shifted the narrative from hyper-growth to a more cautious defensive stance. The Buy Case: A Value Opportunity? bsx stock buy or sell

: Management announced a $2 billion share repurchase program for Q2, signaling confidence in the stock's long-term value. Data at Heart Rhythm 2026 highlight key Boston

: Many analysts, including those from Barclays and Goldman Sachs , see the current price (near its 52-week low of ~$59) as an attractive entry point with predicted upsides ranging from 37% to over 50%. : Management announced a $2 billion share repurchase

: Despite trimming price targets, the consensus remains a Moderate Buy .

: The company reported Q1 2026 revenue of $5.20B and adjusted EPS of $0.80, both slightly beating market expectations.

: Fresh data from the Heart Rhythm 2026 conference continues to support the safety and efficacy of key franchises like FARAPULSE and WATCHMAN . The Sell Case: Rising Risks